Kyorin Pharmaceutical Co Ltd – Product Pipeline Review

Global Markets Direct’s, ‘Kyorin Pharmaceutical Co Ltd – Product Pipeline Review – 2016’, provides an overview of the Kyorin Pharmaceutical Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kyorin Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kyorin Pharmaceutical Co Ltd

The report provides overview of Kyorin Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kyorin Pharmaceutical Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kyorin Pharmaceutical Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kyorin Pharmaceutical Co Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kyorin Pharmaceutical Co Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kyorin Pharmaceutical Co Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Kyorin Pharmaceutical Co Ltd Snapshot 7

Kyorin Pharmaceutical Co Ltd Overview 7

Key Facts 7

Kyorin Pharmaceutical Co Ltd - Research and Development Overview 8

Key Therapeutic Areas 8

Kyorin Pharmaceutical Co Ltd - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Kyorin Pharmaceutical Co Ltd - Pipeline Products Glance 17

Kyorin Pharmaceutical Co Ltd - Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Kyorin Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Kyorin Pharmaceutical Co Ltd - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Kyorin Pharmaceutical Co Ltd - Drug Profiles 22

AX-10479 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

ibudilast - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

KCA-1490 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

KRP-109 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

KRP-203 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

KRPAM-1977X - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

KRPAM-1977Y - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MN-002 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MTG-201 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

neramexane mesylate - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule to Inhibit PDE4 for Inflammation - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

tipelukast - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

vibegron - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Kyorin Pharmaceutical Co Ltd - Pipeline Analysis 54

Kyorin Pharmaceutical Co Ltd - Pipeline Products by Target 54

Kyorin Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 56

Kyorin Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 57

Kyorin Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 58

Kyorin Pharmaceutical Co Ltd - Dormant Projects 60

Kyorin Pharmaceutical Co Ltd - Discontinued Pipeline Products 61

Discontinued Pipeline Product Profiles 61

KEA-0477 61

KRP-104 61

KRP-105 61

KRP-110 61

KRP-203 61

MK-0767 62

ranirestat 62

tipelukast 62

Kyorin Pharmaceutical Co Ltd - Locations And Subsidiaries 63

Head Office 63

Other Locations & Subsidiaries 63

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Kyorin Pharmaceutical Co Ltd, Key Facts 7

Kyorin Pharmaceutical Co Ltd – Pipeline by Indication, 2016 9

Kyorin Pharmaceutical Co Ltd – Pipeline by Stage of Development, 2016 11

Kyorin Pharmaceutical Co Ltd – Monotherapy Products in Pipeline, 2016 12

Kyorin Pharmaceutical Co Ltd – Partnered Products in Pipeline, 2016 13

Kyorin Pharmaceutical Co Ltd – Partnered Products/ Combination Treatment Modalities, 2016 14

Kyorin Pharmaceutical Co Ltd – Out-Licensed Products in Pipeline, 2016 15

Kyorin Pharmaceutical Co Ltd – Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Kyorin Pharmaceutical Co Ltd – Phase III, 2016 17

Kyorin Pharmaceutical Co Ltd – Phase II, 2016 18

Kyorin Pharmaceutical Co Ltd – Phase I, 2016 19

Kyorin Pharmaceutical Co Ltd – Preclinical, 2016 20

Kyorin Pharmaceutical Co Ltd – Discovery, 2016 21

Kyorin Pharmaceutical Co Ltd – Pipeline by Target, 2016 55

Kyorin Pharmaceutical Co Ltd – Pipeline by Route of Administration, 2016 56

Kyorin Pharmaceutical Co Ltd – Pipeline by Molecule Type, 2016 57

Kyorin Pharmaceutical Co Ltd – Pipeline Products by Mechanism of Action, 2016 59

Kyorin Pharmaceutical Co Ltd – Dormant Developmental Projects,2016 60

Kyorin Pharmaceutical Co Ltd – Discontinued Pipeline Products, 2016 61

Kyorin Pharmaceutical Co Ltd, Other Locations 63

Kyorin Pharmaceutical Co Ltd, Subsidiaries 64

List of Figures

List of Figures

Kyorin Pharmaceutical Co Ltd – Pipeline by Top 10 Indication, 2016 9

Kyorin Pharmaceutical Co Ltd – Pipeline by Stage of Development, 2016 11

Kyorin Pharmaceutical Co Ltd – Monotherapy Products in Pipeline, 2016 12

Kyorin Pharmaceutical Co Ltd – Partnered Products in Pipeline, 2016 13

Kyorin Pharmaceutical Co Ltd – Out-Licensed Products in Pipeline, 2016 15

Kyorin Pharmaceutical Co Ltd – Pipeline by Top 10 Target, 2016 54

Kyorin Pharmaceutical Co Ltd – Pipeline by Route of Administration, 2016 56

Kyorin Pharmaceutical Co Ltd – Pipeline by Molecule Type, 2016 57

Kyorin Pharmaceutical Co Ltd – Pipeline Products by Top 10 Mechanism of Action, 2016 58

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports